Timor Kadir

Timor Kadir is a co-founder and Chief Technology Officer of Optellum, an Oxford-based medtech company that has developed the world's only FDA-cleared, CE-MDR, and UKCA-approved AI decision-support platform for early lung cancer diagnosis. He is one of a group of computer scientists who came together at the University of Oxford's world-renowned Computer Vision Laboratory, where the foundational research underpinning Optellum's Virtual Nodule Clinic was developed over more than a decade.

As CTO, Timor leads the technical development of Optellum's AI platform, which automatically identifies at-risk patients, calculates a clinically validated Lung Cancer Prediction (LCP) score from imaging data, and supports physicians in making earlier, more accurate diagnostic decisions — without the need for invasive procedures on benign lesions. Optellum's Virtual Nodule Clinic is now deployed at leading healthcare systems across the US and UK, and the company has established strategic partnerships with GE Healthcare and Intuitive, the global leader in robotic-assisted surgery.

In September 2022, Optellum raised $14 million in a Series A led by Mercia, with co-investment from Intuitive Ventures and Black Opal Ventures, to accelerate commercial expansion in the UK and US and advance the platform into personalised therapy decisions. Under the leadership of its founding team, Optellum has become the market leader in AI-enabled lung cancer diagnosis, addressing a disease responsible for 1.8 million deaths annually worldwide.